Daniel Pinschewer serves as Professor of Virology at the University of Basel, Switzerland. After graduation from medical school he trained as a postdoctoral fellow in molecular virology at The Scripps Research Center (La Jolla, CA, USA) and in immunology at the University of Zurich (Zurich, Switzerland). Prior to his current appointment he was an associate professor of immunology at the University of Geneva (Geneva, Switzerland).
In recent years, Daniel Pinschewer’s academic research and contributions to science have focused on the reverse engineering of arenaviruses for vectorized vaccine delivery, on the role of alarmins in protective antiviral T cell responses, on subversion of B cell responses in chronic infection and on mechanisms of microbial pathogenesis.
Daniel Pinschewer has been the recipient of career awards from the European Research Council (ERC starting grant) and from the Swiss National Science Foundation (stipendiary professorship). Patented discoveries made in his laboratory represent the technological basis of the vaccine and immunotherapy company HOOKIPA Pharma Inc. (Nasdaq HOOK), which he has co-founded. National and international honors include the Georges-Köhler-Prize of the German Society for Immunology and the Loeffler-Frosch-Prize of the Society for Virology, the Debiopharm Group Life Sciences Award, the Pfizer Research Prize and the Prix Leenaards.
